Merrimack enroll last patient in Phase II study of breast cancer drug

Merrimack Pharmaceuticals has enrolled the last patient in the second cohort of a two-cohort randomized Phase II clinical trial of MM-121 (SAR256212) in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news